Analytical Data
-
Gene name
GRA6
- Application
-
Alternative Names
Antigen p32 (Protein p33)
-
Species
TOV-Toxoplasma gondii
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q27003
-
Expression Region
35-150aa
-
Molecular Weight
38.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GRA6, a protein encoded by the Toxoplasma gondii genome, is classified as a dense granule protein and plays a crucial role in the parasite's interaction with host cells. Research on GRA6 has gained significant attention due to its potential implications in understanding the biology of T. gondii, a major intracellular parasite responsible for toxoplasmosis, a disease affecting millions worldwide. This protein is secreted into the host cell cytosol during the invasion and is implicated in modulating host immune responses. Studies suggest that GRA6 can interact with various host cell proteins, potentially altering signaling pathways and enabling the parasite to evade host defenses. Understanding the structure and function of GRA6 is essential for developing new therapeutic strategies and vaccines against T. gondii. Moreover, the insights gained from GRA6 may offer broader implications for other apicomplexan parasites, highlighting its relevance in parasitology and immunology research. As a key player in the pathogenesis of toxoplasmosis, elucidating the mechanisms by which GRA6 contributes to the parasite's survival and manipulation of host cellular processes remains a pivotal area of investigation.
